ZA200301524B - Vaccine. - Google Patents

Vaccine. Download PDF

Info

Publication number: ZA200301524B
Authority: ZA; South Africa
Prior art keywords: cbpx; proteins; vaccine; family; lytx
Prior art date: 2000-09-15

Application number

ZA200301524A

Other languages

English (en)

Inventor

Philippe Hermand

Laferriere Craig Antony Joseph

Yves Lobet

Jan Poolman

Original Assignee

Smithkline Beecham Biolog

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-09-15

Filing date

2003-02-25

Publication date

2004-04-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9899575&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200301524(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-02-25 Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog

2004-04-21 Publication of ZA200301524B publication Critical patent/ZA200301524B/en

Links

229960005486 vaccine Drugs 0.000 title claims description 74
108090000623 proteins and genes Proteins 0.000 claims description 95
102000004169 proteins and genes Human genes 0.000 claims description 91
239000000203 mixture Substances 0.000 claims description 30
230000002163 immunogen Effects 0.000 claims description 22
101710099976 Photosystem I P700 chlorophyll a apoprotein A1 Proteins 0.000 claims description 17
238000000034 method Methods 0.000 claims description 17
108020001507 fusion proteins Proteins 0.000 claims description 16
102000037865 fusion proteins Human genes 0.000 claims description 16
229920002704 polyhistidine Polymers 0.000 claims description 13
101100420868 Anuroctonus phaiodactylus phtx gene Proteins 0.000 claims description 12
101710183389 Pneumolysin Proteins 0.000 claims description 11
239000002671 adjuvant Substances 0.000 claims description 11
230000028993 immune response Effects 0.000 claims description 11
101710164918 Choline-binding protein Proteins 0.000 claims description 9
206010033078 Otitis media Diseases 0.000 claims description 8
206010035664 Pneumonia Diseases 0.000 claims description 8
238000004519 manufacturing process Methods 0.000 claims description 8
241000193998 Streptococcus pneumoniae Species 0.000 claims description 7
230000002265 prevention Effects 0.000 claims description 7
108700039582 histidine triad Proteins 0.000 claims description 6
208000015181 infectious disease Diseases 0.000 claims description 6
239000003814 drug Substances 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 4
238000002156 mixing Methods 0.000 claims description 4
241000124008 Mammalia Species 0.000 claims description 2
241000194017 Streptococcus Species 0.000 claims 1
235000018102 proteins Nutrition 0.000 description 82
108091007433 antigens Proteins 0.000 description 31
102000036639 antigens Human genes 0.000 description 31
239000000427 antigen Substances 0.000 description 27
150000004676 glycans Chemical class 0.000 description 27
229920001282 polysaccharide Polymers 0.000 description 27
239000005017 polysaccharide Substances 0.000 description 27
150000001413 amino acids Chemical class 0.000 description 19
230000027455 binding Effects 0.000 description 15
210000003491 skin Anatomy 0.000 description 15
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 13
229960001231 choline Drugs 0.000 description 13
230000004044 response Effects 0.000 description 11
241000894006 Bacteria Species 0.000 description 10
210000004207 dermis Anatomy 0.000 description 10
239000012634 fragment Substances 0.000 description 9
238000009472 formulation Methods 0.000 description 7
230000004927 fusion Effects 0.000 description 7
230000004224 protection Effects 0.000 description 7
241000606768 Haemophilus influenzae Species 0.000 description 6
108010076504 Protein Sorting Signals Proteins 0.000 description 6
210000001744 T-lymphocyte Anatomy 0.000 description 6
241000700605 Viruses Species 0.000 description 6
108091016312 choline binding proteins Proteins 0.000 description 6
229940001442 combination vaccine Drugs 0.000 description 6
229960003983 diphtheria toxoid Drugs 0.000 description 6
239000013598 vector Substances 0.000 description 6
108090000695 Cytokines Proteins 0.000 description 5
102000004127 Cytokines Human genes 0.000 description 5
108020004414 DNA Proteins 0.000 description 5
230000000890 antigenic effect Effects 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
230000006698 induction Effects 0.000 description 5
239000007924 injection Substances 0.000 description 5
238000002347 injection Methods 0.000 description 5
229940035032 monophosphoryl lipid a Drugs 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
108090000765 processed proteins & peptides Proteins 0.000 description 5
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
229960000814 tetanus toxoid Drugs 0.000 description 5
239000003053 toxin Substances 0.000 description 5
231100000765 toxin Toxicity 0.000 description 5
108700012359 toxins Proteins 0.000 description 5
238000002965 ELISA Methods 0.000 description 4
241000588650 Neisseria meningitidis Species 0.000 description 4
208000035109 Pneumococcal Infections Diseases 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
201000010099 disease Diseases 0.000 description 4
230000000694 effects Effects 0.000 description 4
210000002615 epidermis Anatomy 0.000 description 4
239000007788 liquid Substances 0.000 description 4
230000001681 protective effect Effects 0.000 description 4
229940031000 streptococcus pneumoniae Drugs 0.000 description 4
108010077805 Bacterial Proteins Proteins 0.000 description 3
102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 description 3
241000991587 Enterovirus C Species 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
108010052285 Membrane Proteins Proteins 0.000 description 3
102000018697 Membrane Proteins Human genes 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
201000005702 Pertussis Diseases 0.000 description 3
101710188053 Protein D Proteins 0.000 description 3
101710132893 Resolvase Proteins 0.000 description 3
230000005875 antibody response Effects 0.000 description 3
238000013459 approach Methods 0.000 description 3
230000002238 attenuated effect Effects 0.000 description 3
210000004899 c-terminal region Anatomy 0.000 description 3
239000002775 capsule Substances 0.000 description 3
230000009089 cytolysis Effects 0.000 description 3
238000012217 deletion Methods 0.000 description 3
230000037430 deletion Effects 0.000 description 3
229940047650 haemophilus influenzae Drugs 0.000 description 3
230000005847 immunogenicity Effects 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
239000000411 inducer Substances 0.000 description 3
238000007918 intramuscular administration Methods 0.000 description 3
238000013508 migration Methods 0.000 description 3
230000005012 migration Effects 0.000 description 3
108020004707 nucleic acids Proteins 0.000 description 3
102000039446 nucleic acids Human genes 0.000 description 3
150000007523 nucleic acids Chemical class 0.000 description 3
239000007764 o/w emulsion Substances 0.000 description 3
244000052769 pathogen Species 0.000 description 3
108010021711 pertactin Proteins 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
238000013519 translation Methods 0.000 description 3
238000002255 vaccination Methods 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
229920000936 Agarose Polymers 0.000 description 2
208000031729 Bacteremia Diseases 0.000 description 2
108010078791 Carrier Proteins Proteins 0.000 description 2
102000014914 Carrier Proteins Human genes 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
201000009906 Meningitis Diseases 0.000 description 2
241000588655 Moraxella catarrhalis Species 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
241000588653 Neisseria Species 0.000 description 2
102000005348 Neuraminidase Human genes 0.000 description 2
108010006232 Neuraminidase Proteins 0.000 description 2
101710116435 Outer membrane protein Proteins 0.000 description 2
208000009362 Pneumococcal Pneumonia Diseases 0.000 description 2
206010035728 Pneumonia pneumococcal Diseases 0.000 description 2
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
241000700159 Rattus Species 0.000 description 2
108010006785 Taq Polymerase Proteins 0.000 description 2
108010031133 Transferrin-Binding Protein A Proteins 0.000 description 2
108010031127 Transferrin-Binding Protein B Proteins 0.000 description 2
239000002253 acid Substances 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 2
229940001007 aluminium phosphate Drugs 0.000 description 2
229910000147 aluminium phosphate Inorganic materials 0.000 description 2
159000000013 aluminium salts Chemical class 0.000 description 2
229910000329 aluminium sulfate Inorganic materials 0.000 description 2
238000010171 animal model Methods 0.000 description 2
230000000844 anti-bacterial effect Effects 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
229960000074 biopharmaceutical Drugs 0.000 description 2
230000000981 bystander Effects 0.000 description 2
239000000969 carrier Substances 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
210000002421 cell wall Anatomy 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
235000012000 cholesterol Nutrition 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
230000002349 favourable effect Effects 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
210000004201 immune sera Anatomy 0.000 description 2
229940042743 immune sera Drugs 0.000 description 2
230000003993 interaction Effects 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
239000012139 lysis buffer Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
239000012528 membrane Substances 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
229940124733 pneumococcal vaccine Drugs 0.000 description 2
230000001915 proofreading effect Effects 0.000 description 2
229940070741 purified protein derivative of tuberculin Drugs 0.000 description 2
238000011160 research Methods 0.000 description 2
230000000241 respiratory effect Effects 0.000 description 2
239000000523 sample Substances 0.000 description 2
230000028327 secretion Effects 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
210000000434 stratum corneum Anatomy 0.000 description 2
208000022218 streptococcal pneumonia Diseases 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
229960001295 tocopherol Drugs 0.000 description 2
229930003799 tocopherol Natural products 0.000 description 2
235000010384 tocopherol Nutrition 0.000 description 2
239000011732 tocopherol Substances 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 description 2
238000001262 western blot Methods 0.000 description 2
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
NJNWCIAPVGRBHO-UHFFFAOYSA-N 2-hydroxyethyl-dimethyl-[(oxo-$l^{5}-phosphanylidyne)methyl]azanium Chemical group OCC[N+](C)(C)C#P=O NJNWCIAPVGRBHO-UHFFFAOYSA-N 0.000 description 1
108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 1
101710186708 Agglutinin Proteins 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241000710929 Alphavirus Species 0.000 description 1
201000001178 Bacterial Pneumonia Diseases 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
101100453077 Botryococcus braunii HDR gene Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000282461 Canis lupus Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
238000011537 Coomassie blue staining Methods 0.000 description 1
101150036540 Copb1 gene Proteins 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
241000194033 Enterococcus Species 0.000 description 1
241000194032 Enterococcus faecalis Species 0.000 description 1
241000194031 Enterococcus faecium Species 0.000 description 1
241000709661 Enterovirus Species 0.000 description 1
208000000832 Equine Encephalomyelitis Diseases 0.000 description 1
101000874355 Escherichia coli (strain K12) Outer membrane protein assembly factor BamA Proteins 0.000 description 1
108060002716 Exonuclease Proteins 0.000 description 1
208000000666 Fowlpox Diseases 0.000 description 1
101000597577 Gluconacetobacter diazotrophicus (strain ATCC 49037 / DSM 5601 / CCUG 37298 / CIP 103539 / LMG 7603 / PAl5) Outer membrane protein Proteins 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
101100406392 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) omp26 gene Proteins 0.000 description 1
101710133291 Hemagglutinin-neuraminidase Proteins 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000873843 Homo sapiens Sorting and assembly machinery component 50 homolog Proteins 0.000 description 1
101710146024 Horcolin Proteins 0.000 description 1
241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
108010002616 Interleukin-5 Proteins 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
101710189395 Lectin Proteins 0.000 description 1
241000186781 Listeria Species 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
101710179758 Mannose-specific lectin Proteins 0.000 description 1
101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
201000005505 Measles Diseases 0.000 description 1
108010090054 Membrane Glycoproteins Proteins 0.000 description 1
102000012750 Membrane Glycoproteins Human genes 0.000 description 1
208000005647 Mumps Diseases 0.000 description 1
241001529936 Murinae Species 0.000 description 1
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
208000005141 Otitis Diseases 0.000 description 1
241000709664 Picornaviridae Species 0.000 description 1
102100035181 Plastin-1 Human genes 0.000 description 1
241000607142 Salmonella Species 0.000 description 1
241000710961 Semliki Forest virus Species 0.000 description 1
241000607768 Shigella Species 0.000 description 1
241000710960 Sindbis virus Species 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
102100035853 Sorting and assembly machinery component 50 homolog Human genes 0.000 description 1
-1 Sp128 Chemical class 0.000 description 1
241000191940 Staphylococcus Species 0.000 description 1
241000191963 Staphylococcus epidermidis Species 0.000 description 1
206010061372 Streptococcal infection Diseases 0.000 description 1
201000005010 Streptococcus pneumonia Diseases 0.000 description 1
241000193996 Streptococcus pyogenes Species 0.000 description 1
241000193990 Streptococcus sp. 'group B' Species 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
206010043376 Tetanus Diseases 0.000 description 1
241000906446 Theraps Species 0.000 description 1
102220499889 Uncharacterized protein DOCK8-AS1_D15S_mutation Human genes 0.000 description 1
206010046865 Vaccinia virus infection Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
101710151579 Zinc metalloproteinase Proteins 0.000 description 1
FHICGHSMIPIAPL-HDYAAECPSA-N [2-[3-[6-[3-[(5R,6aS,6bR,12aR)-10-[6-[2-[2-[4,5-dihydroxy-3-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]ethoxy]ethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-5-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carbonyl]peroxypropyl]-5-[[5-[8-[3,5-dihydroxy-4-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]octoxy]-3,4-dihydroxy-6-methyloxan-2-yl]methoxy]-3,4-dihydroxyoxan-2-yl]propoxymethyl]-5-hydroxy-3-[(6S)-6-hydroxy-2,6-dimethylocta-2,7-dienoyl]oxy-6-methyloxan-4-yl] (2E,6S)-6-hydroxy-2-(hydroxymethyl)-6-methylocta-2,7-dienoate Chemical compound C=C[C@@](C)(O)CCC=C(C)C(=O)OC1C(OC(=O)C(\CO)=C\CC[C@](C)(O)C=C)C(O)C(C)OC1COCCCC1C(O)C(O)C(OCC2C(C(O)C(OCCCCCCCCC3C(C(OC4C(C(O)C(O)CO4)O)C(O)CO3)O)C(C)O2)O)C(CCCOOC(=O)C23C(CC(C)(C)CC2)C=2[C@@]([C@]4(C)CCC5C(C)(C)C(OC6C(C(O)C(O)C(CCOCCC7C(C(O)C(O)CO7)OC7C(C(O)C(O)CO7)O)O6)O)CC[C@]5(C)C4CC=2)(C)C[C@H]3O)O1 FHICGHSMIPIAPL-HDYAAECPSA-N 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
238000007792 addition Methods 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000000910 agglutinin Substances 0.000 description 1
229940037003 alum Drugs 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
230000003416 augmentation Effects 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
238000010009 beating Methods 0.000 description 1
235000021028 berry Nutrition 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
208000002352 blister Diseases 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
210000004081 cilia Anatomy 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
238000010367 cloning Methods 0.000 description 1
230000024203 complement activation Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
238000010276 construction Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
230000001461 cytolytic effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
229940009976 deoxycholate Drugs 0.000 description 1
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
238000013461 design Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000001784 detoxification Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
206010013023 diphtheria Diseases 0.000 description 1
229940079593 drug Drugs 0.000 description 1
208000019258 ear infection Diseases 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
230000006862 enzymatic digestion Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
230000009088 enzymatic function Effects 0.000 description 1
238000001976 enzyme digestion Methods 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
238000012869 ethanol precipitation Methods 0.000 description 1
102000013165 exonuclease Human genes 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
238000001476 gene delivery Methods 0.000 description 1
230000002949 hemolytic effect Effects 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
230000028996 humoral immune response Effects 0.000 description 1
230000008348 humoral response Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000006054 immunological memory Effects 0.000 description 1
230000002480 immunoprotective effect Effects 0.000 description 1
230000003308 immunostimulating effect Effects 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
208000022760 infectious otitis media Diseases 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000021633 leukocyte mediated immunity Effects 0.000 description 1
230000029226 lipidation Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
230000008774 maternal effect Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
244000005700 microbiome Species 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
229940031346 monovalent vaccine Drugs 0.000 description 1
208000010805 mumps infectious disease Diseases 0.000 description 1
210000004897 n-terminal region Anatomy 0.000 description 1
MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
229960000210 nalidixic acid Drugs 0.000 description 1
210000001989 nasopharynx Anatomy 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
150000003833 nucleoside derivatives Chemical class 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
206010033675 panniculitis Diseases 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
108010049148 plastin Proteins 0.000 description 1
238000007747 plating Methods 0.000 description 1
229960001973 pneumococcal vaccines Drugs 0.000 description 1
229920002627 poly(phosphazenes) Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229940031937 polysaccharide vaccine Drugs 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000037452 priming Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
235000004252 protein component Nutrition 0.000 description 1
239000001397 quillaja saponaria molina bark Substances 0.000 description 1
230000000601 reactogenic effect Effects 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
238000012552 review Methods 0.000 description 1
201000005404 rubella Diseases 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000012723 sample buffer Substances 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
150000007949 saponins Chemical class 0.000 description 1
208000007056 sickle cell anemia Diseases 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
238000010911 splenectomy Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
210000004304 subcutaneous tissue Anatomy 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
125000001493 tyrosinyl group Chemical class [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
208000007089 vaccinia Diseases 0.000 description 1
230000001018 virulence Effects 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0208—Specific bacteria not otherwise provided for
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Mycology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Virology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Communicable Diseases (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Pulmonology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

ZA200301524A 2000-09-15 2003-02-25 Vaccine. ZA200301524B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0022742.1A GB0022742D0 (en)	2000-09-15	2000-09-15	Vaccine

Publications (1)

Publication Number	Publication Date
ZA200301524B true ZA200301524B (en)	2004-04-21

Family

ID=9899575

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
ZA200301524A ZA200301524B (en)	2000-09-15	2003-02-25	Vaccine.
ZA200301526A ZA200301526B (en)	2000-09-15	2003-02-25	Vaccine against streptococcus pneumoniae.

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
ZA200301526A ZA200301526B (en)	2000-09-15	2003-02-25	Vaccine against streptococcus pneumoniae.

Country Status (25)

Country	Link
US (5)	US20060051361A1 (cs)
EP (6)	EP2314313B1 (cs)
JP (3)	JP4880184B2 (cs)
KR (5)	KR100805991B1 (cs)
CN (3)	CN100486642C (cs)
AT (1)	ATE516815T1 (cs)
AU (4)	AU2002220548B2 (cs)
BR (2)	BR0113821A (cs)
CA (2)	CA2421998C (cs)
CY (1)	CY1111915T1 (cs)
CZ (2)	CZ305324B6 (cs)
DK (1)	DK1317279T3 (cs)
ES (4)	ES2545876T3 (cs)
GB (1)	GB0022742D0 (cs)
HK (1)	HK1057698A1 (cs)
HU (2)	HUP0301043A3 (cs)
IL (4)	IL154607A0 (cs)
MX (2)	MXPA03002265A (cs)
NO (2)	NO336186B1 (cs)
NZ (2)	NZ524286A (cs)
PL (2)	PL209247B1 (cs)
PT (1)	PT1317279E (cs)
SI (1)	SI1317279T1 (cs)
WO (2)	WO2002022167A2 (cs)
ZA (2)	ZA200301524B (cs)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7078042B2 (en) *	1995-09-15	2006-07-18	Uab Research Foundation	Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
US6800744B1 (en)	1997-07-02	2004-10-05	Genome Therapeutics Corporation	Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
US7129339B1 (en)	1997-07-02	2006-10-31	Sanofi Pasteur Limited	Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
US20010016200A1 (en)	1998-04-23	2001-08-23	Briles David E.	Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
US7128918B1 (en) *	1998-12-23	2006-10-31	Id Biomedical Corporation	Streptococcus antigens
TR200102739T2 (tr) *	1999-03-19	2001-12-21	Smithkline Beecham Biologicals S.A.	Aşı
US7074415B2 (en) *	2000-06-20	2006-07-11	Id Biomedical Corporation	Streptococcus antigens
GB0115176D0 (en)	2001-06-20	2001-08-15	Chiron Spa	Capular polysaccharide solubilisation and combination vaccines
AU2002351623A1 (en)	2001-12-20	2003-07-09	Shire Biochem Inc.	Streptococcus antigens
IL164242A0 (en) *	2002-04-02	2005-12-18	Univ Ben Gurion	Protein-based streptococcus pneumoniae vaccines
US8691243B2 (en)	2002-04-02	2014-04-08	Ben-Gurion University Of The Negev Research And Development Authority	Protein-based Streptococcus pneumoniae vaccine
SI2353608T1 (sl)	2002-10-11	2020-12-31	Glaxosmithkline Biologicals Sa	Polipeptidna cepiva za široko zaščito proti hipervirulentnim meningokoknim linijam
GB0227346D0 (en)	2002-11-22	2002-12-31	Chiron Spa	741
US8229903B2 (en) *	2002-12-19	2012-07-24	International Business Machines Corporation	Suggesting data interpretations and patterns for updating policy documents
WO2004067030A2 (en) *	2003-01-30	2004-08-12	Chiron Srl	Injectable vaccines against multiple meningococcal serogroups
DE602004010376T2 (de) *	2003-03-13	2008-10-23	Glaxosmithkline Biologicals S.A.	Verfahren zur reinigung von bakteriellem cytolysin
EP1477802A1 (en) *	2003-05-16	2004-11-17	Erasmus Universiteit Rotterdam	Method for selecting and producing vaccine components and vaccines based thereon
GB0323103D0 (en)	2003-10-02	2003-11-05	Chiron Srl	De-acetylated saccharides
CA2885040C (en)	2003-10-02	2018-10-30	Novartis Vaccines And Diagnostics S.R.L.	Liquid vaccines for multiple meningococcal serogroups
EP1791562A4 (en) *	2004-09-21	2008-07-09	Sanofi Pasteur Inc	ADDITIONAL POLYACOCARPHARATE-PROTEIN CONJUGATES AND VACCINES FROM MENINGOCOCKS
KR102220506B1 (ko)	2005-04-08	2021-03-02	와이어쓰 엘엘씨	다가 폐렴구균 다당류-단백질 접합체 조성물
AU2011253684B8 (en) *	2005-04-08	2013-07-11	Wyeth Llc	Multivalent pneumococcal polysaccharide-protein conjugate composition
GB0522765D0 (en)	2005-11-08	2005-12-14	Chiron Srl	Combination vaccine manufacture
GB0524066D0 (en)	2005-11-25	2006-01-04	Chiron Srl	741 ii
TWI457133B (zh)	2005-12-13	2014-10-21	Glaxosmithkline Biolog Sa	新穎組合物
DK3017827T3 (en)	2005-12-22	2019-02-18	Glaxosmithkline Biologicals Sa	Pneumococcal polysaccharide conjugate VACCINE
WO2007087064A2 (en) *	2005-12-28	2007-08-02	The Uab Research Foundation	Pneumococcal serotypes
US8808707B1 (en)	2006-05-08	2014-08-19	Wyeth Llc	Pneumococcal dosing regimen
JP2010501012A (ja) *	2006-08-17	2010-01-14	ザユーエービーリサーチファウンデーション	免疫原性ＰｃｐＡポリペプチドおよびその使用
EP2476431A1 (en) *	2007-05-24	2012-07-18	GlaxoSmithKline Biologicals S.A.	Lyophilised antigen composition
CN101883583B (zh)	2007-06-26	2017-05-17	葛兰素史密丝克莱恩生物有限公司	含有肺炎链球菌荚膜多糖缀合物的疫苗
GB0713880D0 (en)	2007-07-17	2007-08-29	Novartis Ag	Conjugate purification
US20160228500A9 (en) *	2007-07-23	2016-08-11	Martina Ochs	Immunogenic Polypeptides and Monoclonal Antibodies
CA2694466A1 (en) *	2007-07-23	2009-01-29	Sanofi Pasteur Limited	Immunogenic polypeptides and monoclonal antibodies
GB0714963D0 (en)	2007-08-01	2007-09-12	Novartis Ag	Compositions comprising antigens
US20100278819A1 (en) *	2007-09-14	2010-11-04	Katholieke Universiteit Leuven	Streptococcus pneumoniae vaccines
CN105044337A (zh) *	2008-02-01	2015-11-11	圣诺菲·帕斯图尔有限公司	用于诊断肺炎链球菌的试验
CA2716706C (en)	2008-03-03	2014-02-18	Irm Llc	Compounds and compositions as tlr activity modulators
EP2411045A1 (en)	2009-03-24	2012-02-01	Novartis AG	Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
WO2010144734A1 (en)	2009-06-10	2010-12-16	Novartis Ag	Benzonaphthyridine-containing vaccines
TWI445708B (zh)	2009-09-02	2014-07-21	Irm Llc	作為ｔｌｒ活性調節劑之化合物及組合物
ES2443952T3 (es)	2009-09-02	2014-02-21	Novartis Ag	Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
CN102695523A (zh)	2009-09-10	2012-09-26	诺华有限公司	针对呼吸道疾病的组合疫苗
CN101690810B (zh) *	2009-10-21	2011-08-17	辽宁益康生物股份有限公司	一种鸡新城疫、传染性支气管炎、减蛋综合征、禽流感四联灭活疫苗佐剂及其制备方法
WO2011057148A1 (en)	2009-11-05	2011-05-12	Irm Llc	Compounds and compositions as tlr-7 activity modulators
BR112012014624A8 (pt)	2009-12-15	2017-12-26	Novartis Ag	suspensão homogênea de compostos de imunopotenciação e usos dos destes
WO2011075822A1 (en)	2009-12-22	2011-06-30	Sanofi Pasteur Limited	Immunogenic compositions and related methods
WO2011075823A1 (en) *	2009-12-22	2011-06-30	Sanofi Pasteur Limited	Immunogenic compositions
GB201003920D0 (en) *	2010-03-09	2010-04-21	Glaxosmithkline Biolog Sa	Method of treatment
GB201003922D0 (en)	2010-03-09	2010-04-21	Glaxosmithkline Biolog Sa	Conjugation process
WO2011119759A1 (en)	2010-03-23	2011-09-29	Irm Llc	Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
WO2012072769A1 (en)	2010-12-01	2012-06-07	Novartis Ag	Pneumococcal rrgb epitopes and clade combinations
CN103501808A (zh) *	2010-12-03	2014-01-08	赛诺菲巴斯德有限公司	用于针对肺炎链球菌免疫的组合物
KR20140033127A (ko) *	2011-05-17	2014-03-17	글락소스미스클라인 바이오로지칼즈 에스.에이.	스트렙토코쿠스 뉴모니애에 대한 백신
WO2013131983A1 (en)	2012-03-07	2013-09-12	Novartis Ag	Adjuvanted formulations of streptococcus pneumoniae antigens
JP2014000016A (ja) *	2012-06-15	2014-01-09	National Agriculture & Food Research Organization	豚丹毒菌の新規な抗原タンパク質、その遺伝子、及び組換えベクターとその利用
RU2510281C2 (ru) *	2012-06-22	2014-03-27	Общество с ограниченной ответственностью "Эпитоп" (ООО "Эпитоп")	ВАКЦИНА ПРОТИВ ПНЕВМОНИИ, ВЫЗЫВАЕМОЙ Streptococcus pneumoniae, НА ОСНОВЕ ГИБРИДНОГО БЕЛКА
CA2888300A1 (en) *	2012-10-17	2014-04-24	Glaxosmithkline Biologicals S.A.	Immunogenic composition
GB201218660D0 (en)	2012-10-17	2012-11-28	Glaxosmithkline Biolog Sa	Immunogenic composition
ES2642967T3 (es)	2013-01-01	2017-11-20	Agfa Graphics Nv	Copolímeros (de etileno, vinilacetal) y precursores de plancha de impresión litográfica que incluyen tales copolímeros
WO2014118305A1 (en)	2013-02-01	2014-08-07	Novartis Ag	Intradermal delivery of immunological compositions comprising toll-like receptor agonists
US11160855B2 (en)	2014-01-21	2021-11-02	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US20150344530A1 (en) *	2014-05-29	2015-12-03	Subhash V. Kapre	Synthetic Peptides as Carriers for Conjugation with Polysaccharides
US9107906B1 (en)	2014-10-28	2015-08-18	Adma Biologics, Inc.	Compositions and methods for the treatment of immunodeficiency
US20190079404A1 (en)	2016-03-16	2019-03-14	Agfa Nv	Method for processing a lithographic printing plate
US11844829B2 (en)	2016-12-28	2023-12-19	Zalvac Ab	Microparticles from Streptococcus pneumoniae as vaccine antigens
US10259865B2 (en)	2017-03-15	2019-04-16	Adma Biologics, Inc.	Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
KR102634811B1 (ko)	2017-06-10	2024-02-06	인벤트프라이즈 인크.	면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신
US10729763B2 (en)	2017-06-10	2020-08-04	Inventprise, Llc	Mixtures of polysaccharide-protein pegylated compounds
BR112020016314A2 (pt)	2018-02-12	2020-12-15	Inimmune Corporation	Compostos ou um sais farmaceuticamente aceitáveis, composição farmacêutica, kit, e, métodos para elicitar, intensificar ou modificar uma resposta imunológica, para tratar, prevenir ou reduzir a suscetibilidade a câncer, para tratar, prevenir ou reduzir a suscetibilidade a uma doença infecciosa, para tratar, prevenir ou reduzir a suscetibilidade a uma alergia, para tratar, prevenir ou reduzir a suscetibilidade a uma afecção autoimune, para tratar, prevenir ou reduzir a suscetibilidade em um sujeito à infecção bacteriana, viral, priônica, autoimunidade, câncer ou alergia, para tratar, prevenir ou reduzir a suscetibilidade à autoimunidade, alergia, reperfusão de isquemia ou sepse, para tratar, prevenir ou reduzir a gravidade de ataques epiléticos e para tratar, prevenir ou reduzir a suscetibilidade a doenças oculares como degeneração macular, hipertensão ocular e infecção ocular
CA3133185A1 (en) *	2019-03-13	2020-09-17	St. Jude Children's Research Hospital	Vaccine compositions and methods for reducing transmission of streptococcus pneumoniae
EP3778253A1 (en)	2019-08-13	2021-02-17	Agfa Nv	Method for processing a lithographic printing plate
US12053515B2 (en)	2020-08-10	2024-08-06	Inventprise, Inc.	Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24F
US11473093B2 (en)	2020-11-04	2022-10-18	Eligo Bioscience	Cutibacterium acnes recombinant phages, method of production and uses thereof
WO2024239063A1 (en) *	2023-05-22	2024-11-28	Gpn Vaccines Pty Ltd	Modified streptococcal immunogen and uses thereof

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4235877A (en)	1979-06-27	1980-11-25	Merck & Co., Inc.	Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en)	1979-11-13	1983-02-08	Likhite Vilas V	Antigen compounds
IL61904A (en)	1981-01-13	1985-07-31	Yeda Res & Dev	Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
BE889979A (fr)	1981-08-14	1982-02-15	Smith Kline Rit	Procede de preparation de polysaccharides bacteriens capsulaires antigeniques purifies, produits obtenus et leur utilisation
US5360897A (en) *	1981-08-31	1994-11-01	The University Of Rochester	Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
US4761283A (en) *	1983-07-05	1988-08-02	The University Of Rochester	Immunogenic conjugates
US4882317A (en) *	1984-05-10	1989-11-21	Merck & Co., Inc.	Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US4596556A (en)	1985-03-25	1986-06-24	Bioject, Inc.	Hypodermic injection apparatus
US4709017A (en)	1985-06-07	1987-11-24	President And Fellows Of Harvard College	Modified toxic vaccines
US5173294A (en)	1986-11-18	1992-12-22	Research Foundation Of State University Of New York	Dna probe for the identification of haemophilus influenzae
US4941880A (en)	1987-06-19	1990-07-17	Bioject, Inc.	Pre-filled ampule and non-invasive hypodermic injection device assembly
US4940460A (en)	1987-06-19	1990-07-10	Bioject, Inc.	Patient-fillable and non-invasive hypodermic injection device assembly
US4790824A (en)	1987-06-19	1988-12-13	Bioject, Inc.	Non-invasive hypodermic injection device
US5339163A (en)	1988-03-16	1994-08-16	Canon Kabushiki Kaisha	Automatic exposure control device using plural image plane detection areas
US4912094B1 (en) *	1988-06-29	1994-02-15	Ribi Immunochem Research Inc.	Modified lipopolysaccharides and process of preparation
US5006914A (en) *	1988-12-02	1991-04-09	Advanced Technology Materials, Inc.	Single crystal semiconductor substrate articles and semiconductor devices comprising same
CA2005704C (en) *	1988-12-16	2003-02-11	James C. Paton	Pneumolysin mutants and pneumococcal vaccines made therefrom
US5064413A (en)	1989-11-09	1991-11-12	Bioject, Inc.	Needleless hypodermic injection device
US5312335A (en)	1989-11-09	1994-05-17	Bioject Inc.	Needleless hypodermic injection device
SE466259B (sv)	1990-05-31	1992-01-20	Arne Forsgren	Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
CA2059693C (en)	1991-01-28	2003-08-19	Peter J. Kniskern	Polysaccharide antigens from streptococcus pneumoniae
CA2059692C (en) *	1991-01-28	2004-11-16	Peter J. Kniskern	Pneumoccoccal polysaccharide conjugate vaccine
DE69226167T2 (de)	1991-02-15	1998-11-12	The Uab Research Foundation, Birmingham, Alabama	Strukturgen von pneumokokken-protein
US6592876B1 (en)	1993-04-20	2003-07-15	Uab Research Foundation	Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
US5980909A (en) *	1991-02-15	1999-11-09	Uab Research Foundation	Epitopic regions of pneumococcal surface protein A
US5476929A (en)	1991-02-15	1995-12-19	Uab Research Foundation	Structural gene of pneumococcal protein
US5552146A (en)	1991-08-15	1996-09-03	Board Of Regents, The University Of Texas System	Methods and compositions relating to useful antigens of Moraxella catarrhalis
GB9118204D0 (en)	1991-08-23	1991-10-09	Weston Terence E	Needle-less injector
US5371197A (en) *	1991-09-24	1994-12-06	Merck & Co., Inc.	Protein-dimeric polysaccharide conjugate vaccine
AU671649B2 (en)	1992-06-18	1996-09-05	President And Fellows Of Harvard College	Diphtheria toxin vaccines
KR100278157B1 (ko)	1992-06-25	2001-01-15	장 스테판느	보조약을 함유하는 백신 조성물
US5383851A (en)	1992-07-24	1995-01-24	Bioject Inc.	Needleless hypodermic injection device
CA2123580C (en) *	1992-09-16	2005-04-26	James B. Dale	Antigen of hybrid m protein and carrier for group a streptococcal vaccine
US5569189A (en)	1992-09-28	1996-10-29	Equidyne Systems, Inc.	hypodermic jet injector
US5334144A (en)	1992-10-30	1994-08-02	Becton, Dickinson And Company	Single use disposable needleless injector
GB9224584D0 (en)	1992-11-23	1993-01-13	Connaught Lab	Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases
ES2109685T5 (es)	1993-03-23	2005-09-01	Smithkline Beecham Biologicals S.A.	Composiciones para vacunas que contienen monofosforil-lipido a 3-o-desacilado.
JP3429313B2 (ja)	1993-05-18	2003-07-22	オハイオ・ステイト・リサーチ・ファウンデーション	中耳炎ワクチン
DE122009000058I1 (de)	1993-09-22	2009-12-31	Jackson H M Found Military Med	Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten
GB9326253D0 (en)	1993-12-23	1994-02-23	Smithkline Beecham Biolog	Vaccines
WO1995024176A1 (en)	1994-03-07	1995-09-14	Bioject, Inc.	Ampule filling device
US5466220A (en)	1994-03-08	1995-11-14	Bioject, Inc.	Drug vial mixing and transfer device
US5866135A (en) *	1994-04-21	1999-02-02	North American Vaccine, Inc.	Group A streptococcal polysaccharide immunogenic compositions and methods
US5917017A (en)	1994-06-08	1999-06-29	President And Fellows Of Harvard College	Diphtheria toxin vaccines bearing a mutated R domain
EP1167378B1 (en)	1994-07-15	2011-05-11	University of Iowa Research Foundation	Immunomodulatory oligonucleotides
US5565204A (en)	1994-08-24	1996-10-15	American Cyanamid Company	Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5599302A (en)	1995-01-09	1997-02-04	Medi-Ject Corporation	Medical injection system and method, gas spring thereof and launching device using gas spring
UA56132C2 (uk)	1995-04-25	2003-05-15	Смітклайн Бічем Байолоджікалс С.А.	Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6440425B1 (en)	1995-05-01	2002-08-27	Aventis Pasteur Limited	High molecular weight major outer membrane protein of moraxella
US5730723A (en)	1995-10-10	1998-03-24	Visionary Medical Products Corporation, Inc.	Gas pressured needle-less injection device and method
US5843464A (en)	1995-06-02	1998-12-01	The Ohio State University	Synthetic chimeric fimbrin peptides
HUP0600442A3 (en)	1995-06-07	2007-03-28	Biochem Vaccines Inc	Streptococcal heat shock proteins members of the hsp70 family
GB9513074D0 (en)	1995-06-27	1995-08-30	Cortecs Ltd	Novel anigen
US6290970B1 (en)	1995-10-11	2001-09-18	Aventis Pasteur Limited	Transferrin receptor protein of Moraxella
US5893397A (en)	1996-01-12	1999-04-13	Bioject Inc.	Medication vial/syringe liquid-transfer apparatus
US6090576A (en)	1996-03-08	2000-07-18	Connaught Laboratories Limited	DNA encoding a transferrin receptor of Moraxella
GB9607549D0 (en)	1996-04-11	1996-06-12	Weston Medical Ltd	Spring-powered dispensing device
US6245335B1 (en) *	1996-05-01	2001-06-12	The Rockefeller University	Choline binding proteins for anti-pneumococcal vaccines
JP2000511411A (ja)	1996-05-01	2000-09-05	ザロックフェラーユニヴァーシティ	抗―肺炎球菌ワクチン用のコリン結合タンパク質
US5744417A (en)	1996-05-02	1998-04-28	Lyondell Petrochemical Company	Supported catalyst
US7341727B1 (en)	1996-05-03	2008-03-11	Emergent Product Development Gaithersburg Inc.	M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
AR008242A1 (es)	1996-06-18	1999-12-29	Alza Corp	Dispositivo para atravesar el estrato corneo de una superficie corporal
EP0956289A4 (en)	1996-08-16	2004-10-13	Smithkline Beecham Corp	NOVEL PROKARYOTA POLYNUCLEOTIDES AND POLYPEPTIDES AND USES THEREOF
US5882871A (en)	1996-09-24	1999-03-16	Smithkline Beecham Corporation	Saliva binding protein
US5882896A (en)	1996-09-24	1999-03-16	Smithkline Beecham Corporation	M protein
DE69737125T3 (de) *	1996-10-31	2015-02-26	Human Genome Sciences, Inc.	Streptococcus pneumoniae-Antigene und Impfstoffe
JP2002503087A (ja)	1996-11-12	2002-01-29	リージェンツオブザユニバーシティオブミネソタ	ストレプトコッカス・ニューモニアのｃ３結合タンパク質
US5980898A (en)	1996-11-14	1999-11-09	The United States Of America As Represented By The U.S. Army Medical Research & Material Command	Adjuvant for transcutaneous immunization
DK0957972T3 (da)	1996-12-20	2003-07-21	Alza Corp	Anordning og fremgangsmåde til at forøge transdermal middelflux
DE19708537A1 (de)	1997-03-03	1998-09-10	Biotechnolog Forschung Gmbh	Neues Oberflächenprotein (SpsA-Protein) von Streptococcus pneumoniae etc.
FR2763244B1 (fr) *	1997-05-14	2003-08-01	Pasteur Merieux Serums Vacc	Composition vaccinale multivalente a porteur mixte
US5993412A (en)	1997-05-19	1999-11-30	Bioject, Inc.	Injection apparatus
ATE380867T1 (de)	1997-06-03	2007-12-15	Sanofi Pasteur Ltd	Lactoferrinrezeptorgen von moraxella
CA2297374A1 (en)	1997-07-21	1999-01-28	North American Vaccine, Inc.	Modified immunogenic pneumolysin, compositions and their use as vaccines
US6224880B1 (en) *	1997-09-24	2001-05-01	Merck & Co., Inc.	Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
KR20010024299A (ko)	1997-09-24	2001-03-26	리전츠 오브 더 유니버스티 오브 미네소타	스트렙토코쿠스 뉴모니애로부터의 사람 보체 ｃ3 분해단백질분해효소
EP0916726A1 (en) *	1997-11-13	1999-05-19	Rijksuniversiteit te Groningen	Attaching substances to micro-organisms
WO1999027961A1 (en)	1997-12-02	1999-06-10	Powderject Vaccines, Inc.	Transdermal delivery of particulate vaccine compositions
IT1298087B1 (it)	1998-01-08	1999-12-20	Fiderm S R L	Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US6709658B1 (en) *	1998-02-12	2004-03-23	Wyeth Holdings Corporation	Pneumococcal vaccines formulated with interleukin-12
NZ507983A (en) *	1998-04-07	2004-03-26	St	A polypeptide comprising the amino acid of an n- terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
NZ507717A (en)	1998-04-07	2004-02-27	Medimmune Inc	Derivatives of pneumococcal choline binding proteins for vaccines
WO1999053940A1 (en)	1998-04-23	1999-10-28	Uab Research Foundation	PNEUMOCOCCAL SURFACE PROTEIN C(PspC), EPITOPIC REGIONS AND STRAIN SELECTION THEREOF, AND USES THEREFOR
GB9812613D0 (en)	1998-06-11	1998-08-12	Smithkline Beecham Biolog	Vaccine
CN1352691A (zh)	1998-09-24	2002-06-05	美国明尼苏达州大学	来自肺炎链球菌的人补体c3降解性多肽
GB2359228A (en)	1998-11-17	2001-08-15	Schlumberger Technology Corp	Transmitting information over a communication link
WO2000029434A2 (en)	1998-11-19	2000-05-25	St. Jude Children's Research Hospital	PNEUMOCOCCAL CHOLINE BINDING PROTEINS, CbpG AND CbpD, DIAGNOSTIC AND THERAPEUTIC USES THEREOF
AU776828B2 (en) *	1998-12-21	2004-09-23	Medimmune, Llc	Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
EP1034792A1 (en) *	1999-03-11	2000-09-13	Pasteur Merieux Serums Et Vaccins	Intranasal delivery of pneumococcal polysaccharide vaccines
TR200102739T2 (tr) *	1999-03-19	2001-12-21	Smithkline Beecham Biologicals S.A.	Aşı
EP1731166B1 (en)	1999-06-10	2011-03-09	MedImmune, LLC	Streptococcus pneumoniae proteins and vaccines
EP1189632A4 (en) *	1999-06-10	2002-08-21	Uab Research Foundation	Pneumococcal surface protein combination vaccine
US6319224B1 (en)	1999-08-20	2001-11-20	Bioject Medical Technologies Inc.	Intradermal injection system for injecting DNA-based injectables into humans
US6494865B1 (en)	1999-10-14	2002-12-17	Becton Dickinson And Company	Intradermal delivery device including a needle assembly

2000
- 2000-09-15 GB GBGB0022742.1A patent/GB0022742D0/en not_active Ceased
2001
- 2001-09-12 MX MXPA03002265A patent/MXPA03002265A/es active IP Right Grant
- 2001-09-12 SI SI200131001T patent/SI1317279T1/sl unknown
- 2001-09-12 ES ES01984627.8T patent/ES2545876T3/es not_active Expired - Lifetime
- 2001-09-12 EP EP10178332.2A patent/EP2314313B1/en not_active Expired - Lifetime
- 2001-09-12 US US10/380,575 patent/US20060051361A1/en not_active Abandoned
- 2001-09-12 ES ES01984626T patent/ES2368902T3/es not_active Expired - Lifetime
- 2001-09-12 KR KR1020037003731A patent/KR100805991B1/ko not_active Expired - Fee Related
- 2001-09-12 CZ CZ2003-756A patent/CZ305324B6/cs not_active IP Right Cessation
- 2001-09-12 EP EP09173889.8A patent/EP2140878B1/en not_active Expired - Lifetime
- 2001-09-12 BR BR0113821-9A patent/BR0113821A/pt active Pending
- 2001-09-12 CZ CZ2003-757A patent/CZ305343B6/cs not_active IP Right Cessation
- 2001-09-12 US US10/380,563 patent/US20040081662A1/en not_active Abandoned
- 2001-09-12 BR BR0113822-7A patent/BR0113822A/pt not_active IP Right Cessation
- 2001-09-12 CN CNB018157467A patent/CN100486642C/zh not_active Expired - Fee Related
- 2001-09-12 CN CNB018157483A patent/CN1253205C/zh not_active Expired - Fee Related
- 2001-09-12 DK DK01984626.0T patent/DK1317279T3/da active
- 2001-09-12 HU HU0301043A patent/HUP0301043A3/hu not_active Application Discontinuation
- 2001-09-12 AU AU2002220548A patent/AU2002220548B2/en not_active Ceased
- 2001-09-12 ES ES09173889.8T patent/ES2551097T3/es not_active Expired - Lifetime
- 2001-09-12 PL PL361395A patent/PL209247B1/pl unknown
- 2001-09-12 KR KR1020087020661A patent/KR100991916B1/ko not_active Expired - Fee Related
- 2001-09-12 AT AT01984626T patent/ATE516815T1/de active
- 2001-09-12 EP EP10179133A patent/EP2305297A1/en not_active Ceased
- 2001-09-12 NZ NZ524286A patent/NZ524286A/en not_active IP Right Cessation
- 2001-09-12 JP JP2002526417A patent/JP4880184B2/ja not_active Expired - Fee Related
- 2001-09-12 JP JP2002526416A patent/JP4903975B2/ja not_active Expired - Fee Related
- 2001-09-12 IL IL15460701A patent/IL154607A0/xx unknown
- 2001-09-12 AU AU2002238193A patent/AU2002238193B2/en not_active Ceased
- 2001-09-12 AU AU2054802A patent/AU2054802A/xx active Pending
- 2001-09-12 NZ NZ524287A patent/NZ524287A/en not_active IP Right Cessation
- 2001-09-12 EP EP01984627.8A patent/EP1317280B1/en not_active Expired - Lifetime
- 2001-09-12 PT PT01984626T patent/PT1317279E/pt unknown
- 2001-09-12 WO PCT/EP2001/010568 patent/WO2002022167A2/en active Search and Examination
- 2001-09-12 IL IL15460801A patent/IL154608A0/xx unknown
- 2001-09-12 KR KR1020117026231A patent/KR101268790B1/ko not_active Expired - Fee Related
- 2001-09-12 WO PCT/EP2001/010570 patent/WO2002022168A2/en active Application Filing
- 2001-09-12 AU AU3819302A patent/AU3819302A/xx active Pending
- 2001-09-12 MX MXPA03002264A patent/MXPA03002264A/es active IP Right Grant
- 2001-09-12 ES ES10178332.2T patent/ES2659400T3/es not_active Expired - Lifetime
- 2001-09-12 CN CN2009101285337A patent/CN101502648B/zh not_active Expired - Fee Related
- 2001-09-12 PL PL361401A patent/PL210198B1/pl unknown
- 2001-09-12 KR KR10-2003-7003732A patent/KR20030031188A/ko not_active Application Discontinuation
- 2001-09-12 CA CA2421998A patent/CA2421998C/en not_active Expired - Fee Related
- 2001-09-12 KR KR1020107014638A patent/KR20100091241A/ko not_active Ceased
- 2001-09-12 CA CA2422002A patent/CA2422002C/en not_active Expired - Fee Related
- 2001-09-12 EP EP10179135A patent/EP2305298A1/en not_active Withdrawn
- 2001-09-12 EP EP01984626A patent/EP1317279B1/en not_active Revoked
- 2001-09-12 HU HU0301092A patent/HUP0301092A3/hu unknown
2003
- 2003-02-24 IL IL154608A patent/IL154608A/en not_active IP Right Cessation
- 2003-02-24 IL IL154607A patent/IL154607A/en not_active IP Right Cessation
- 2003-02-25 ZA ZA200301524A patent/ZA200301524B/en unknown
- 2003-02-25 ZA ZA200301526A patent/ZA200301526B/en unknown
- 2003-03-14 NO NO20031183A patent/NO336186B1/no not_active IP Right Cessation
- 2003-03-14 NO NO20031184A patent/NO337730B1/no not_active IP Right Cessation
- 2003-11-19 HK HK03108447.9A patent/HK1057698A1/xx not_active IP Right Cessation
2007
- 2007-05-07 US US11/745,006 patent/US20080081050A1/en not_active Abandoned
2010
- 2010-08-13 US US12/855,734 patent/US20110008419A1/en not_active Abandoned
2011
- 2011-09-12 JP JP2011198277A patent/JP2012006969A/ja active Pending
- 2011-10-06 CY CY20111100958T patent/CY1111915T1/el unknown
2013
- 2013-12-10 US US14/101,995 patent/US20140099339A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP2314313A1 (en)	2011-04-27
ZA200301526B (en)	2004-06-04
CA2421998C (en)	2015-01-06
CN101502648A (zh)	2009-08-12
ES2551097T3 (es)	2015-11-16
HUP0301092A2 (hu)	2003-09-29
IL154607A (en)	2010-11-30
KR20030031187A (ko)	2003-04-18
CZ305343B6 (cs)	2015-08-12
SI1317279T1 (sl)	2011-11-30
NO20031183L (no)	2003-05-13
IL154608A0 (en)	2003-09-17
NO20031184L (no)	2003-05-14
HK1057698A1 (en)	2004-04-16
CA2422002C (en)	2013-06-18
ES2368902T3 (es)	2011-11-23
JP2004508416A (ja)	2004-03-18
BR0113821A (pt)	2003-06-24
NZ524286A (en)	2005-05-27
US20060051361A1 (en)	2006-03-09
NZ524287A (en)	2005-03-24
US20140099339A1 (en)	2014-04-10
HUP0301043A3 (en)	2011-03-28
EP2314313B1 (en)	2017-12-27
CN1477970A (zh)	2004-02-25
KR20030031188A (ko)	2003-04-18
US20080081050A1 (en)	2008-04-03
EP2140878B1 (en)	2015-08-26
HUP0301043A2 (hu)	2003-09-29
DK1317279T3 (da)	2011-10-24
AU2002238193B2 (en)	2005-05-12
NO20031184D0 (no)	2003-03-14
WO2002022167A2 (en)	2002-03-21
CA2421998A1 (en)	2002-03-21
PT1317279E (pt)	2011-10-11
JP2004508417A (ja)	2004-03-18
KR100805991B1 (ko)	2008-02-26
EP1317279A2 (en)	2003-06-11
CY1111915T1 (el)	2015-11-04
MXPA03002265A (es)	2004-12-03
CN1694723A (zh)	2005-11-09
HUP0301092A3 (en)	2011-03-28
EP2305297A1 (en)	2011-04-06
US20110008419A1 (en)	2011-01-13
ES2545876T3 (es)	2015-09-16
MXPA03002264A (es)	2004-12-03
BR0113822A (pt)	2003-06-24
CZ305324B6 (cs)	2015-08-05
CZ2003757A3 (cs)	2003-10-15
PL361395A1 (en)	2004-10-04
CN100486642C (zh)	2009-05-13
AU2002220548B2 (en)	2005-04-14
CN101502648B (zh)	2013-07-03
WO2002022168A2 (en)	2002-03-21
KR20100091241A (ko)	2010-08-18
GB0022742D0 (en)	2000-11-01
CZ2003756A3 (cs)	2003-10-15
KR100991916B1 (ko)	2010-11-04
PL361401A1 (en)	2004-10-04
EP2140878A1 (en)	2010-01-06
KR101268790B1 (ko)	2013-05-29
WO2002022168A3 (en)	2002-06-27
EP1317279B1 (en)	2011-07-20
ES2659400T3 (es)	2018-03-15
AU2054802A (en)	2002-03-26
CA2422002A1 (en)	2002-03-21
JP4903975B2 (ja)	2012-03-28
ATE516815T1 (de)	2011-08-15
EP2305298A1 (en)	2011-04-06
JP4880184B2 (ja)	2012-02-22
NO20031183D0 (no)	2003-03-14
AU3819302A (en)	2002-03-26
WO2002022167A3 (en)	2002-06-27
CN1253205C (zh)	2006-04-26
IL154607A0 (en)	2003-09-17
EP1317280B1 (en)	2015-07-15
KR20080080683A (ko)	2008-09-04
PL210198B1 (pl)	2011-12-30
KR20110132483A (ko)	2011-12-07
EP1317280A2 (en)	2003-06-11
JP2012006969A (ja)	2012-01-12
PL209247B1 (pl)	2011-08-31
NO337730B1 (no)	2016-06-13
US20040081662A1 (en)	2004-04-29
NO336186B1 (no)	2015-06-08
IL154608A (en)	2010-11-30

Publication	Publication Date	Title
EP1317280B1 (en)	2015-07-15	Vaccine against streptococcus pneumoniae
AU2002238193A1 (en)	2002-06-13	Vaccine against streptococcus pneumoniae
AU2002220548A1 (en)	2002-06-13	Vaccine against streptococcus penumoniae
ZA200404803B (en)	2005-08-29	Streptococcus pneumoniae vaccine.